Skip to main content
Equibles

Dalma Kayati

Analyst

Guggenheim

Equibles does not estimate personal net worth.

About Dalma Kayati

Dalma Kayati is recorded as Analyst at Guggenheim. Dalma Kayati has spoken on 1 earnings call across 1 company, most recently for Neurocrine Biosciences Inc on July 30, 2026. The companies whose calls Dalma Kayati spoke on are classified in the Healthcare sector.

Dalma Kayati on recent calls

“So on the Frederick Ataxia program, what should we expect from the 2027 Phase 1 readout? More in detail. Which tissue compartments will you report frataxin protein levels from buccal cells, skin, or muscle?”
Analyst — Guggenheim, Neurocrine Biosciences Conference Call and Webcast of Q2 2026 Financial Results ·

Affiliation history

  • Guggenheim

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity